This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Quartz Bio SA Supports Debiopharm Group Precision Medicine Bioinformatics

LAUSANNE, Switzerland, July 4, 2013 /PRNewswire/ --

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that they have signed a one-year collaboration agreement with Quartz Bio, the Clinical Bioinformatics Research Organization leader in precision biomarker discovery.

Under the research framework, Quartz Bio will apply its leading expertise in bioinformatics to support Debiopharm translational projects in terms of computational analyses and biomarker discovery. Projects are expected to range from preclinical Next-Generation Sequencing to clinical biomarker data analyses.

"We are delighted to collaborate with Debiopharm," said Dr. Jerome Wojcik, CEO of Quartz Bio. "Debiopharm's pioneering biomarker projects are a unique opportunity for Quartz Bio to contribute to the implementation of Precision Medicine, thus demonstrating that bioinformatics science can bring substantial benefits to patients."

"We look forward to collaborating with Quartz Bio," commented Dr. Hiroaki Tanaka, Director of Personalized Medicine at Debiopharm. "Their longstanding clinical bioinformatics experience made them an ideal partner to support our biomarker projects in our clinical trials and extract from data the relevant information required for personalized therapy development."

About Quartz Bio

Quartz Bio SA is a clinical bioinformatics service company specialized in exploratory biomarker data analyses for the generation of precision medicine hypotheses. Quartz Bio provides modular data analysis solutions to the major steps of the biomarker development process. These include: biomarker study design, biomarker data quality control, statistical analysis and scientific reporting. The capital of the company is entirely owned by its employees, who are scientists from diverse educational backgrounds with a common track record of 6 to 10 years clinical bioinformatics experience in the pharmaceutical sector.

For more information, please visit the company's web site: http://www.quartzbio.com

About Debiopharm Group™

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,615.50 +174.91 1.00%
S&P 500 2,089.95 +22.31 1.08%
NASDAQ 5,083.6960 +43.92 0.87%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs